We found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleRoflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge.AuthorsLouw, C; Williams, Z; Venter, L; Leichtl, S; Schmid-Wirlitsch, C; Bredenbroker, D; Bardin, P GAbstractRoflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, is currently in clinical development for the treatment of asthma.PublicationRespiration; international review of thoracic diseases, 2007, Vol 74, Issue 4, p411ISSN0025-7931Publication typeJournal ArticleDOI10.1159/000095677